FDA nominee sidesteps questions on abortion pill, agency layoffs and other issues
- During his confirmation hearing, Dr. Marty Makary responded to questions about regulatory processes and the FDA's handling of vaccine meetings, citing examples of missed opportunities for discussion from other political administrations.
- Senator Patty Murray expressed concern over the FDA's canceled vaccine meeting, stating it undermines public health recommendations that have existed for decades.
- Makary faced inquiries about the mifepristone abortion pill but refrained from making firm commitments regarding its regulatory status, emphasizing the need to review data first.
- Amid staffing changes, including recent layoffs, Makary's nomination is timely, with pressure on the FDA from various sides regarding its decision-making processes and transparency.
79 Articles
79 Articles
FDA Nominee Makary Calls for ‘More Humility in the Medical Establishment’
In his confirmation hearing to be commissioner of the Food and Drug Administration, Dr. Martin Makary on Thursday decried the hubris of the medical establishment that he said was leading to a distrust of medical professionals by the American public. “We need more humility in the medical establishment,” Makary told the Senate Committee on Health, Education, Labor, and Pensions, which also heard the testimony of Trump’s nominee to lead the Nation…
FDA nominee evades abortion pill questions
President Donald Trump's pick to lead the Food and Drug Administration largely sidestepped questions Thursday from senators about how he would handle numerous pressing issues before the agency, including recent layoffs, a canceled vaccine meeting and the continued availability of…
Coverage Details
Bias Distribution
- 43% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage